Effect of Caloric Restriction and AMPK Activation on Hepatic Nuclear Receptor, Biotransformation Enzyme, and Transporter Expression in Lean and Obese Mice

被引:9
作者
Kulkarni, Supriya R. [1 ]
Xu, Jialin [1 ]
Donepudi, Ajay C. [1 ]
Wei, Wei [1 ]
Slitt, Angela L. [1 ]
机构
[1] Univ Rhode Isl, Coll Pharm, Dept Biomed & Pharmaceut Sci, Kingston, RI 02881 USA
关键词
gene expression; liver; nuclear receptor; steatosis; transport; FATTY LIVER-DISEASE; PROTEIN-KINASE; LIPID-METABOLISM; MOUSE-LIVER; PPAR-ALPHA; PHASE-I; SIRT1; RESISTANCE; INDUCTION; LEPTIN;
D O I
10.1007/s11095-013-1140-2
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Fatty liver alters liver transporter expression. Caloric restriction (CR), the recommended therapy to reverse fatty liver, increases Sirtuin1 deacetylase activity in liver. This study evaluated whether CR and CR mimetics reversed obesity-induced transporter expression in liver and hepatocytes. mRNA and protein expression was determined in adult lean (lean) and leptin-deficient obese (OB) mice fed ad libitum or placed on 40% (kCal) reduced diet. Hepatocytes were isolated from lean and OB mice, treated with AMP Kinase activators, and gene expression was determined. CR decreased Oatp1a1, Oatp1b2, and Abcb11 mRNA expression in lean, but not OB mice. CR increased Abcc2 mRNA OB livers, whereas protein expression increased in both genotypes. CR increased Abcc3 protein expression increased in OB livers. CR did not alter Abcc1, 4 and 5 mRNA expression in lean mice but decreased expression in livers of OB mice. CR increased Abcc4 protein in lean, but not OB mice. CR restriction reversed the expression of some, but not all transporters in livers of OB mice. Overall, these data indicate a potential for CR to restore some hepatic transporter changes in OB mice, but suggest a functional leptin axis is needed for reversal of expression for some transporters.
引用
收藏
页码:2232 / 2247
页数:16
相关论文
共 65 条
  • [11] Metabolic benefits from Sirt1 and Sirt1 activators
    Chaudhary, Nilika
    Pfluger, Paul T.
    [J]. CURRENT OPINION IN CLINICAL NUTRITION AND METABOLIC CARE, 2009, 12 (04) : 431 - 437
  • [12] Drug-metabolizing enzyme and transporter expression in a mouse model of diabetes and obesity
    Cheng, Qiuqiong
    Aleksunes, Lauren M.
    Manautou, Jose E.
    Cherrington, Nathan J.
    Scheffer, George L.
    Yamasaki, Hideki
    Slitt, Angela L.
    [J]. MOLECULAR PHARMACEUTICS, 2008, 5 (01) : 77 - 91
  • [13] Peroxisome proliferator-activated receptor γ coactivator 1 in caloric restriction and other models of longevity
    Corton, JC
    Brown-Borg, HM
    [J]. JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES, 2005, 60 (12): : 1494 - 1509
  • [14] Mimetics of caloric restriction include agonists of lipid-activated nuclear receptors
    Corton, JC
    Apte, U
    Anderson, SP
    Limaye, P
    Yoon, L
    Latendresse, J
    Dunn, C
    Everitt, JI
    Voss, KA
    Swanson, C
    Kimbrough, C
    Wong, JS
    Gill, SS
    Chandraratna, RAS
    Kwak, MK
    Kensler, TW
    Stulnig, TM
    Steffensen, KR
    Gustafsson, JÅ
    Mehendale, HM
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (44) : 46204 - 46212
  • [15] Hepatic uptake of bilirubin and its conjugates by the human organic anion transporter SLC21A6
    Cui, Y
    König, J
    Leier, I
    Buchholz, U
    Keppler, D
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (13) : 9626 - 9630
  • [16] An in vitro model of caloric restriction
    de Cabo, R
    Fürer-Galbán, S
    Anson, RM
    Gilman, C
    Gorospe, M
    Lane, MA
    [J]. EXPERIMENTAL GERONTOLOGY, 2003, 38 (06) : 631 - 639
  • [17] Edmisonand J, 2007, CLIN LIVER DIS, V11, p[75, ix]
  • [18] Hepatic Cytochrome P450 Enzyme Alterations in Humans with Progressive Stages of Nonalcoholic Fatty Liver Disease
    Fisher, Craig D.
    Lickteig, Andrew J.
    Augustine, Lisa M.
    Ranger-Moore, James
    Jackson, Jonathan P.
    Ferguson, Stephen S.
    Cherrington, Nathan J.
    [J]. DRUG METABOLISM AND DISPOSITION, 2009, 37 (10) : 2087 - 2094
  • [19] Short-term overexpression of a constitutively active form of AMP-activated protein kinase in the liver leads to mild hypoglycemia and fatty liver
    Foretz, M
    Ancellin, N
    Amdreelli, F
    Saintillan, Y
    Grondin, P
    Kahn, A
    Thorens, B
    Vaulont, S
    Viollet, B
    [J]. DIABETES, 2005, 54 (05) : 1331 - 1339
  • [20] Comparing and contrasting the roles of AMPK and SIRT1 in metabolic tissues
    Fulco, Marcella
    Sartorelli, Vittorio
    [J]. CELL CYCLE, 2008, 7 (23) : 3669 - 3679